Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Pre-Tax Income
Sonoma Pharmaceuticals Inc
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Pre-Tax Income
-$5.1m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
2%
|
|
Johnson & Johnson
NYSE:JNJ
|
Pre-Tax Income
$22.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Pre-Tax Income
$8.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-24%
|
|
Merck & Co Inc
NYSE:MRK
|
Pre-Tax Income
$1.9B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Pre-Tax Income
$6.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
12%
|
CAGR 10-Years
1%
|
See Also
What is Sonoma Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
-5.1m
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Pre-Tax Income amounts to -5.1m USD.
What is Sonoma Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
2%
Over the last year, the Pre-Tax Income growth was 27%. The average annual Pre-Tax Income growth rates for Sonoma Pharmaceuticals Inc have been -21% over the past three years , 17% over the past five years , and 2% over the past ten years .